Erin E Salo-Mullen

List of Publications by Year
in descending order

42 papers	1,894 citations	393982 19 h-index	288905 40 g-index
43 all docs	43 docs citations	43 times ranked	3191 citing authors

#	Article	IF	Citations
1	Evaluating Mismatch Repair Deficiency in Pancreatic Adenocarcinoma: Challenges and Recommendations. Clinical Cancer Research, 2018, 24, 1326-1336.	3.2	281
2	An Emerging Entity: Pancreatic Adenocarcinoma Associated with a Known BRCA Mutation: Clinical Descriptors, Treatment Implications, and Future Directions. Oncologist, 2011, 16, 1397-1402.	1.9	227
3	Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms. Journal of the National Cancer Institute, 2018, 110, 1067-1074.	3.0	170
4	Identification of germline genetic mutations in patients with pancreatic cancer. Cancer, 2015, 121, 4382-4388.	2.0	167
5	Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma. European Journal of Cancer, 2018, 89, 19-26.	1.3	125
6	Mismatch Repairâ€“Deficient Rectal Cancer and Resistance to Neoadjuvant Chemotherapy. Clinical Cancer Research, 2020, 26, 3271-3279.	3.2	118
7	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. Cancer, 2012, 118, 493-499.	2.0	83
8	Therapeutic Implications of Germline Testing in Patients With Advanced Cancers. Journal of Clinical Oncology, 2021, 39, 2698-2709.	0.8	83
9	Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nature Cancer, 2021, 2, 357-365.	5.7	74
10	A Comprehensive Comparison of Early-Onset and Average-Onset Colorectal Cancers. Journal of the National Cancer Institute, 2021, 113, 1683-1692.	3.0	66
11	The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. Clinical Colorectal Cancer, 2012, 11, 304-308.	1.0	52
12	Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches. Expert Review of Gastroenterology and Hepatology, 2016, 10, 1-13.	1.4	39
13	Early-Onset Pancreas Cancer: Clinical Descriptors, Genomics, and Outcomes. Journal of the National Cancer Institute, 2021, 113, 1194-1202.	3.0	35
14	An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice. JAMA Oncology, 2020, 6, 764.	3.4	35
15	Indications for Total Gastrectomy in CDH1 Mutation Carriers and Outcomes of Risk-Reducing Minimally Invasive and Open Gastrectomies. JAMA Surgery, 2020, 155, 1050.	2.2	34
16	Systematic Immunohistochemistry Screening for Lynch Syndrome in Early Age-of-Onset Colorectal Cancer Patients Undergoing Surgical Resection. Journal of the American College of Surgeons, 2012, 214, 61-67.	0.2	32
17	Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer. Genetics in Medicine, 2021, 23, 2105-2113.	1.1	29
18	Germline PALB2 mutation analysis in breast-pancreas cancer families. Journal of Medical Genetics, 2011, 48, 523-525.	1.5	28

#	Article	IF	Citations
19	Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes. Cancer, 2021, 127, 4393-4402.	2.0	24
20	Phase IB trial of cisplatin (C), gemcitabine (G), and veliparib (V) in patients with known or potential BRCA or PALB2-mutated pancreas adenocarcinoma (PC).. Journal of Clinical Oncology, 2014, 32, 4023-4023.	0.8	17
21	CDH1 Missense Variant c.1679C>G (p.T560R) Completely Disrupts Normal Splicing through Creation of a Novel 5â€™ Splice Site. PLoS ONE, 2016, 11, e0165654.	1.1	16
22	Psychosocial factors associated with the uptake of contralateral prophylactic mastectomy among BRCA1/2 mutation noncarriers with newly diagnosed breast cancer. Breast Cancer Research and Treatment, 2017, 162, 297-306.	1.1	16
23	Risk of Metachronous Colorectal Neoplasm after a Segmental Colectomy in Lynch Syndrome Patients According to Mismatch Repair Gene Status. Journal of the American College of Surgeons, 2020, 230, 669-675.	0.2	16
24	Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. Familial Cancer, 2014, 13, 459-467.	0.9	14
25	Educational and Psychosocial Support Needs in Lynch Syndrome: Implementation and Assessment of an Educational Workshop and Support Group. Journal of Genetic Counseling, 2017, 26, 232-243.	0.9	14
26	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. Breast Cancer Research and Treatment, 2014, 145, 625-634.	1.1	11
27	Contiguous gene deletion of chromosome 2p16.3-p21 as a cause of Lynch syndrome. Familial Cancer, 2018, 17, 71-77.	0.9	10
28	Prevalence and Characterization of Biallelic and Monoallelic NTHL1 and MSH3 Variant Carriers From a Pan-Cancer Patient Population. JCO Precision Oncology, 2021, 5, 455-465.	1.5	10
29	Juvenile Polyposis Syndrome Presenting With Familial Gastric Cancer and Massive Gastric Polyposis. Journal of Clinical Oncology, 2012, 30, e229-e232.	0.8	9
30	Factors Influencing Patient Preferences for Telehealth Cancer Genetic Counseling During the COVID-19 Pandemic. JCO Oncology Practice, 2022, 18, e462-e471.	1.4	8
31	Multiple Primary Cancers in Patients Undergoing Tumor-Normal Sequencing Define Novel Associations. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 362-371.	1.1	7
32	Early age of onset and broad cancer spectrum persist in MSH6- and PMS2-associated Lynch syndrome. Genetics in Medicine, 2022, 24, 1187-1195.	1.1	7
33	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. Journal of Clinical Oncology, 2016, 34, e61-e67.	0.8	6
34	Outcome of Pancreatic Cancer Surveillance Among High-Risk Individuals Tested for Germline Mutations in BRCA1 and BRCA2. Cancer Prevention Research, 2019, 12, 599-608.	0.7	6
35	Insertion of an <scp>SVA</scp> element in <scp>MSH2</scp> as a novel cause of Lynch syndrome. Genes Chromosomes and Cancer, 2021, 60, 571-576.	1.5	6
36	Paired Tumor-Normal Sequencing Provides Insights into TP53-Related Cancer Spectrum in Li-Fraumeni Patients. Journal of the National Cancer Institute, 2021, , .	3.0	6

#	Article	IF	Citations
37	Genetic Factors. , 2020, , 180-208.e11.		4
38	Insertion of an Aluâ€like element in MLH1 intron 7 as a novel cause of Lynch syndrome. Molecular Genetics & Genomic Medicine, 2020, 8, e1523.	0.6	4
39	The Genetic Counselor. Advances in Surgery, 2012, 46, 137-153.	0.6	2
40	Disparities in pan-cancer patients undergoing germline cancer risk assessment by self-reported race/ethnicity and ancestry.. Journal of Clinical Oncology, 2021, 39, 10508-10508.	0.8	2
41	Resolving pathogenicity classification for the CDH1 c.[715G>A] (p.Gly239Arg) Variant. European Journal of Human Genetics, 2021, 29, 1103-1109.	1.4	1
42	Variable penetrance of CDH1 mutation diffuse gastric cancer: A genomic analysis.. Journal of Clinical Oncology, 2013, 31, 4082-4082.	0.8	0